By Donna Loyle, communications specialist, LIMR
The Lung-MAP clinical trial is a master screening protocol for recurrent non-small cell lung cancer (NSCLC). The primary objective of this randomized phase II/III clinical study is to test patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol. If assigned to a sub-study, participants will then undergo a new, targeted cancer therapy or a combination of standard care.
Lung-MAP contains both a screening component and a clinical trial component:
- Patients can participate in the screening component either at progression on prior therapy or to be pre-screened while receiving therapy for stage IV or recurrent NSCLC.
- The clinical trial component consists of studies evaluating a drug-biomarker combination for patients determined to have a matching biomarker, and non-match studies evaluating therapies in patients without any of the study biomarkers.
Eligible patients must have been diagnosed with stage IV or recurrent NSCLC. Patients must have received at least one line of systemic therapy for any stage of NSCLC and must have progressed during or after their most recent line of therapy.
The study is approved for all Main Line Health acute care hospitals. Albert DeNittis, MD, and Paul Gilman, MD, are the principal investigators. More information about the Lung-MAP trial is available at www.mainlinehealth.org/research/clinical-trials/lung-map